ENTL Entelos Regs

    


Entelos Inc.



                   Entelos, Inc. ("Entelos" or "the Company")

                                Trading Statement

Entelos, Inc. (LSE:ENTL), a leading life sciences company building predictive
computer models of human physiology and "virtual patients" for drug discovery
and development, today is updating the market ahead of its pre-close period for
the six-month period ended 31 December 2007.

Trading has been in line with management expectations and as previously
announced Entelos expects that 2007 revenues will be in line with the level
reported for 2006 at year-end. The Company has good contract visibility and has
cash and accounts receivables of $9.9 million as at 31 December 2007.

Since its interim report on 19 September 2007, Entelos announced expanding
research in cardiovascular disease with Pfizer Inc., conducting additional
research in diabetes with Johnson & Johnson Pharmaceutical Research and
Development L.L.C., raising capital from Pfizer Ireland Pharmaceuticals and the
Imperium Master Fund, repaying debt related to the acquisition of Iconix
Biosciences, and initiating in silico research in rheumatoid arthritis with a
new pharmaceutical customer, UCB Pharma.

Entelos' in silico R&D and toxicology services, which include clinical trial
simulations and predictive "virtual patient populations", help to move more
drugs forward through the complex R&D process by strategically selecting optimal
patients, doses, clinical trial designs and drug combinations that are both
effective and safe.

In addition, the Company continues to strengthen its business development
capability in both the US and Europe to increase penetration of major
pharmaceutical companies and broaden its customer base to include biotechnology,
cosmetics and other health-care related companies.

The management looks forward to providing further detail on the Company's
full-year performance and future prospects at the time of its preliminary
results in April 2008.

Enquiries

Entelos, Inc.
Alan Blazei, Chief Financial Officer                Tel: +1 650 572 5400
Jill Fujisaki, Vice President, Investor Relations
Evolution Securities
Tim Worlledge/Bobbie Hilliam                        Tel: +44 (0)20 7071 4300
Buchanan Communications
Lisa Baderoon/Mary-Jane Johnson                     Tel: +44 (0)20 7466 5000

About Entelos, Inc.

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines are
discovered, developed, and utilized. The Company leverages its proprietary in
silico disease models, "virtual patients", and toxicology reference systems to
develop safer and more effective drugs and support pharmaceutical R&D and
commercialization. In addition to internal drug programs in rheumatoid arthritis
and women's health, Entelos provides customized technology and research services
to global pharmaceutical and health-care companies in cardiovascular diseases,
asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, and
skin sensitization. The company is also developing a model in oncology and is
collaborating with the FDA to build a model of drug-induced liver injury.
Entelos offers cost-effective drug development capabilities through its
strategic alliance with India-based Jubilant Biosys.

Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jun 2024 to Jul 2024

Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jul 2023 to Jul 2024